Therapy Detail

Therapy Name CBL0137
Therapy Description

CBL0137 is a Curaxin compound that binds to and inhibits the Facilitates Chromatin Transcription (FACT) complex, resulting in apoptosis in cancer cells (PMID: 25402820).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CBL0137 CBL0137 is a Curaxin compound that binds to and inhibits the Facilitates Chromatin Transcription (FACT) complex, resulting in apoptosis in cancer cells (PMID: 25402820).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01905228 Phase I CBL0137 A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting